Search in:

Cancer Management and Research Volume 13, 2021 - Issue

Submit an article Journal homepage

Open access

148

Views

CrossRef citations to date

Altmetric

Original Research

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Maen Hussein1 Florida Cancer Specialists, Leesburg, FL, USACorrespondence[email protected]

Marina Maglakelidze2 LLC Arensia Exploratory Medicine, Tbilisi, Georgia

Donald A Richards3 Texas Oncology-Tyler, US Oncology Research, Tyler, TX, USA

Marielle Sabatini4 Saint Leon Hospital, Bayonne, France

Todd A Gersten5 Florida Cancer Specialists, West Palm Beach, FL, USA

Keith Lerro6 Regional Medical Oncology Center, Wilson, NC, USA

Ivan Sinielnikov7 Volyn Regional Oncology Center, Lutsk, Ukraine

Alexander Spira8 Virginia Cancer Specialists, Fairfax, VA, USA;9 US Oncology Research, The Woodlands, TX, USA

Yili Pritchett10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

Joyce M Antal10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

Rajesh Malik10 G1 Therapeutics, Inc., Research Triangle Park, NC, USA

J Thaddeus Beck11 Highlands Oncology Group, Fayetteville, AR, USA

https://orcid.org/0000-0003-1142-2367

show all

Pages 6207-6218 | Published online: 09 Aug 2021

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (12)

Ying Cheng, Lin Wu, Dingzhi Huang, QiMing Wang, Yun Fan, XiQin Zhang, HuiJie Fan, WenXiu Yao, BaoGang Liu, GuoHua Yu, YueYin Pan, Fei Xu, ZhiYong He, XiaoRong Dong, Rui Ma, XuHong Min, XiaoSong Ge, Hualin Chen, Qun Liu, YanPing Hu, Ying Liu, Chen Yang, Yang Yang, Xiucui Li & Li Zhou. (2024) Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung Cancer 188, pages 107455.
Crossref

Claire Falandry, Alan List & Lodovico Balducci. (2023) Cell cycle arrest: A breakthrough in the supportive care of older cancer patients. Journal of the American Geriatrics Society 71:7, pages 2297-2307.
Crossref

Jingyue Qiu, Dandan Sheng, Fei Lin, Peng Jiang & Ning Shi. (2023) The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 14.
Crossref

Mikhail V. Blagosklonny. (2023) Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells. Oncotarget 14:1, pages 193-206.
Crossref

Lodovico Balducci, Claire Falandry & Alan List. (2023) A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest. Drugs & Aging 40:3, pages 263-272.
Crossref

Ling Deng, Li Yang, Shuhan Zhu, Man Li, Yu Wang, Xiaolong Cao, Qiongyao Wang & Linlang Guo. (2023) Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell Death Discovery 9:1.
Crossref

Esin Aysel Kandemir. (2022) Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021. Journal of Oncology Pharmacy Practice 29:1, pages 191-207.
Crossref

Lodovico Balducci, Claire Falandry & Alan List. (2022) New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology. Current Oncology Reports 24:12, pages 1695-1703.
Crossref

Andrea Sbrana, Andrea Antonuzzo & Marco Danova. (2022) Cytokinetic-driven myeloprotection after cytotoxic chemotherapy: from an old idea to a new clinical approach. Supportive Care in Cancer 30:9, pages 7057-7060.
Crossref

Gizem Kayki-Mutlu, Zinnet Sevval Aksoyalp, Leszek Wojnowski & Martin C. Michel. (2022) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn-Schmiedeberg's Archives of Pharmacology 395:8, pages 867-885.
Crossref

Esther S. Kim & Susan J. Keam. (2022) Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use. Drugs & Therapy Perspectives 38:2, pages 64-71.
Crossref

Apar Kishor P. GantiBilly W. LooMichael BassettiCollin BlakelyAnne ChiangThomas A. D'AmicoChristopher D'AvellaAfshin DowlatiRobert J. DowneyMartin EdelmanCharles FlorsheimKathryn A. GoldJonathan W. GoldmanJohn C. GreculaChristine HannWade IamsPuneeth IyengarKaren KellyMaya KhalilMarianna KoczywasRobert E. MerrittNisha MohindraJulian MolinaCesar MoranSaraswati PokharelSonam PuriAngel QinChad RusthovenJacob SandsRafael Santana-DavilaMichael ShafiqueSaiama N. WaqarKristina M. GregoryMiranda Hughes. (2021) Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 19:12, pages 1441-1464.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Articles from other publishers (12)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Citations (12)

Articles from other publishers (12)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date